Celcuity Inc. (CELC)

Celcuity's stock has significantly appreciated due to positive clinical and regulatory advancements for Gedatolisib. In July 2025, the stock surged due to positive topline results from the Phase 3 VIKTORIA-1 clinical trial, leading to public offerings. In November 2025, Celcuity submitted an NDA to the FDA for gedatolisib. In December 2025, updated data at the San Antonio Breast Cancer Symposium reinforced investor confidence. In January 2026, the FDA accepted Celcuity's NDA for gedatolisib, granting it Priority Review.

Celcuity Inc.'s products and services are not subject to demand seasonality. The demand for cancer treatments is driven by disease incidence, progression, and unmet medical needs, rather than by specific calendar seasons or cyclical consumer patterns.

Celcuity, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for solid tumor indications, particularly those involving the PI3K/AKT/mTOR (PAM) pathway. Their lead therapeutic candidate, Gedatolisib, is being developed for breast and prostate cancer. Celcuity also develops the CELsignia companion diagnostic platform to identify specific abnormal cellular processes driving a patient's cancer. The company has a strategic license agreement with Pfizer Inc. for Gedatolisib.

Celcuity Inc. is based in Minneapolis, Minnesota, with a primary focus on the United States market for the development and commercialization of its therapies. The license agreement with Pfizer Inc. suggests potential for global market reach for Gedatolisib.

Celcuity's brand reputation has been overwhelmingly positive due to clinical and regulatory achievements. Positive topline results from the Phase 3 VIKTORIA-1 clinical trial and FDA's granting of Breakthrough Therapy and Fast Track designations have solidified the company's reputation. Analyst sentiment is overwhelmingly positive, with a consensus of 'Moderate Buy'.

Institutional ownership of Celcuity Inc. is significant, standing at 93.1% as of September 2025. Major institutional owners include Baker Bros. Advisors LP, Perceptive Advisors LLC, and BlackRock, Inc. Key individual owners include Brian F. Sullivan and Lance G. Laing.